Longboard Pharmaceuticals

NEWS

Pictured: Bar and line graphs showing increasing t

Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering

Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.

January 3, 2024

2 min read

Tristan Manalac

IN THE PRESS

Press Releases

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

November 12, 2024

7 min read

Press Releases

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 7, 2024

9 min read

Press Releases

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

October 14, 2024

16 min read

Press Releases

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 4, 2024

October 7, 2024

3 min read

Press Releases

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

September 27, 2024

6 min read

Press Releases

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

September 19, 2024

7 min read

FDA

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

July 1, 2024

7 min read

Biotech Beach

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 03, 2024

June 3, 2024

5 min read

Business

Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions

May 13, 2024

2 min read

Biotech Beach

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 06, 2024

May 6, 2024

5 min read

JOBS